【复星医药:盐酸溴己新注射液获药品注册申请受理】复星医药公告,控股子公司重庆药友制药有限责任公司就盐酸溴己新注射液的药品注册申请于近日获国家药品监督管理局受理。盐酸溴己新注射液为复星医药自主研发的化学药品,拟用于在口服给药困难的情况下,肺结核、尘肺病、手术后等疾病的祛痰。

金融界
26 Feb
复星医药公告,控股子公司重庆药友制药有限责任公司就盐酸溴己新注射液的药品注册申请于近日获国家药品监督管理局受理。盐酸溴己新注射液为复星医药自主研发的化学药品,拟用于在口服给药困难的情况下,肺结核、尘肺病、手术后等疾病的祛痰。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10